Valuation: 3billion, Inc.

Market Cap 164B 114M 98.92M 92.08M 84.54M 160M 10.86B 162M 1.09B 426M 5.41B 427M 418M 18.13B P/E 2025
-107x
P/E 2026 * -
Enterprise Value 147M 102K 88.7K 82.56K 75.8K 143K 9.74M 145K 973K 382K 4.85M 383K 375K 16.26M EV / Sales 2025
49x
EV / Sales 2026 * -
Free-Float
75.48%
Yield 2025 *
-
Yield 2026 * -
1 day+11.98%
1 week-7.89%
1 month-15.88%
3 months-61.95%
6 months-66.80%
Current year-71.80%
1 week 4,260
Extreme 4260
5,690
1 month 4,260
Extreme 4260
6,340
Current year 4,260
Extreme 4260
18,690
1 year 4,260
Extreme 4260
20,100
3 years 3,025
Extreme 3025
20,100
5 years 3,025
Extreme 3025
20,100
10 years 3,025
Extreme 3025
20,100
Manager TitleAgeSince
Chief Executive Officer 45 10/10/2016
Director of Finance/CFO 46 01/10/2020
Chief Tech/Sci/R&D Officer 46 01/08/2018
Director TitleAgeSince
Director/Board Member 45 10/10/2016
Director/Board Member 44 10/10/2016
Director/Board Member 44 18/11/2020
Date Insider Type Main position Quantity % Market Cap.
4/16/25 A Others

Chief Financial Officer

44,000 0.1387%
3/7/25 A Fiscal year

Chief Financial Officer

40,000 0.1262%
3/7/25 A Fiscal year 10,000 0.0316%
Change 5-day change 1-year change 3-year change Capi.($)
+11.98%-7.89%-21.77% - 114M
-22.52%-18.18%+95.94%+79.19% 3.72B
-6.66%+1.35%+118.49%+183.54% 3.59B
+14.72%+17.69%+257.69%+288.19% 2.26B
+3.44%+4.55%-27.34%-35.28% 2.17B
-13.22%-18.44%+51.87%-43.31% 1.82B
-2.67%-2.81%+195.95%-45.02% 969M
+6.96%-1.82%-7.40%+21.17% 853M
+1.29%+6.41%-38.87%-11.36% 511M
+7.90%-3.22%-0.27% - 449M
Average +0.12%-3.60%+62.43%+54.64% 1.65B
Weighted average by Cap. -4.99%-3.76%+94.88%+89.27%

Financials

2025 2026 *
Net sales 10.8B 7.51M 6.53M 6.08M 5.58M 10.54M 717M 10.7M 71.66M 28.13M 357M 28.22M 27.6M 1.2B -
Net income -5.8B -4.04M -3.51M -3.27M -3M -5.66M -385M -5.75M -38.49M -15.1M -192M -15.15M -14.82M -643M -
Net Debt -16.9B -11.76M -10.22M -9.51M -8.73M -16.49M -1.12B -16.75M -112M -44.01M -559M -44.16M -43.19M -1.87B -
Logo 3billion, Inc.
3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.
Employees
-
Date Price Change Volume
31/07/26 ₩5,140.00 +11.98% 104,540
30/07/26 ₩4,590.00 -4.47% 166,380
29/07/26 ₩4,805.00 -7.06% 223,136
28/07/26 ₩5,170.00 -9.77% 150,092
27/07/26 ₩5,730.00 +2.69% 112,061

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A394800 Stock